Data from a small study show that severe methotrexate toxicity in patients who are 70 years of age and older and have rheumatic disease may be associated with poor renal function and the use of diuretic treatments.
Search results for: psoriasis
The 2022 ACR Awards of Distinction
During ACR Convergence 2022 in early November, the ACR honored a group of individuals who have made significant contributions to rheumatology research, education and patient care by announcing the recipients of the ACR’s 2022 Awards of Distinction, as well as the 2022 ACR Masters, recognized for their contributions to the field. See the November issue…
Clinical Rheumatology Year in Review—2022
In this overview of clinical updates in rheumatology in the last year, high-impact studies were discussed, including the GLORIA, ORAL Surveillance and MIRROR trials.
Psoriatic Arthritis: Advances in Therapeutics, Imaging & More Presented at ACR Convergence 2022
PHILADELPHIA—Selecting my top 10 picks for abstracts in psoriatic arthritis (PsA) at the ACR Convergence 2022 meeting was not easy because there was a great deal to review and learn from the 139 abstracts submitted to the meeting. I focused first and foremost on advances in therapeutics that encompassed both new and approved therapeutics, novel…
Challenges in Psoriatic Arthritis
PHILADELPHIA—Despite a large and ever-growing number of therapeutic options for our patients with psoriatic disease, it is not uncommon for us come across scenarios in which a patient’s response to therapy does not match our expectations and our shared goals for treatment. We all have those patients—the ones whose joints improve with one drug, but…
Please Hear Me: How Effective Provider-Patient Communication Improved My Psoriatic Arthritis
PHILADELPHIA—“At age 12, I was diagnosed with psoriasis (PsO), followed by a diagnosis of psoriatic arthritis (PsA) at age 30,” said Ashley Krivohlavek of Oklahoma City in a poster presentation at ACR Convergence 2022. “I’m now 38.” Ms. Krivohlavek’s Story In 2020, I had been on an infused biologic for 18 months, but my…
Treat to Target in axSpA
PHILADELPHIA—Treat to target (T2T) is a common phrase in rheumatology these days—and a welcome one.1 Many of us are familiar with what T2T means in rheumatoid arthritis (RA), but we may be less sure of its meaning in axial spondyloarthritis (axSpA). At ACR Convergence 2022, Alexis Ogdie, MD, associate professor of medicine and epidemiology, University of…
Phase 2 Trial Results for Sjögren’s Syndrome & SLE Presented in 2nd Plenary Session at ACR Convergence 2022
PHILADELPHIA—At the second Plenary Session of ACR Convergence on Sunday, Nov. 13, speakers shared compelling efficacy and safety results from two phase 2 trials: remibrutinib for Sjögren’s syndrome and deucravacitinib for moderate to severe systemic lupus erythematosus. Remibrutinib in Phase 2 Sjögren’s Syndrome Trial Thomas Dörner, MD, a professor of rheumatology and clinical immunology for…
Top Research in Axial Spondyloarthritis Presented at ACR Convergence 2022
PHILADELPHIA—Approximately 100 research abstracts on axial spondyloarthritis (axSpA) were accepted for presentation at ACR Convergence 2022. It is exciting to see a wealth of research on axSpA being undertaken worldwide. Here, we highlight important points from 10 of these studies. 1. Abstract 0378: Prevalence of Axial Spondyloarthritis (axSpA) in Patients Treated for Chronic Back Pain…
FDA Approves Ustekinumab for Children with PsA
After examining study data from pediatric patients with both psoriasis and psoriatic arthritis (PsA), the FDA approved ustekinumab as a treatment for patients aged 6–17 years old with PsA.
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 56
- Next Page »